LifeMD appoints Kathleen E. Walsh to Board; grants 75,000 restricted shares and 37,500 stock options

LifeMD, Inc.

Kathleen E. Walsh appointed to Board on Dec 15, 2022; she is President & CEO of Boston Medical Center.
Received 75,000 restricted shares (37,500 vest immediately, 37,500 vest in 2 years).
Also received option to purchase 37,500 shares, vesting in 2 years.
Will receive $6,000 per quarter as Board compensation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kathleen E. Walsh

director

LFMD · LifeMD, Inc.

Effective: 2022-12-15
Filed: December 21, 2022, 6:59 PM ET

On December 15, 2022, LifeMD, Inc. (the “Company”) appointed Kathleen E. Walsh to the board of directors (the “Board”) of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kathleen E. Walsh was appointed as director at LifeMD, Inc..

Action: appointed
Role: director

Exact text from the filing

On December 15, 2022, LifeMD, Inc. (the “Company”) appointed Kathleen E. Walsh to the board of directors (the “Board”) of the Company.

View on SEC.gov

LifeMD, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-036130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.